Aiosyn unveils first results of independent clinical study: improved efficiency and consistency in mitosis counting with Aiosyn Mitosis Breast

By Anna Correas Grifoll
10 September, 2023

Nijmegen, the Netherlands – Aiosyn is proud to announce the first results of an independent clinical performance study conducted for its Aiosyn Mitosis Breast solution. This study was performed at Radboud university medical center (Nijmegen, the Netherlands) and involved a diverse group of certified pathologists from around the globe. 

Counting mitoses in histology slides represents a crucial aspect of assessing tumor proliferation rates and plays a pivotal role in cancer grading. Aiosyn Mitosis Breast is designed to assist pathologists in this tedious and subjective task, offering laboratories an AI-powered solution that significantly increases efficiency and consistency of results.

The study revealed that 75% of participants experienced improved efficiency when supported by Aiosyn Mitosis Breast. On average, pathologists demonstrated a 15.5% increase in productivity while reviewing resections. Importantly, this boost in efficiency was achieved without compromising accuracy. In addition, the algorithm significantly reduced inter-observer variability, resulting in a 32.6% enhancement in consistency among pathologists.

With over 90% of surveyed pathologists expressing their interest in integrating the algorithm into their daily practice, Aiosyn and Radboud university medical center look forward to sharing these groundbreaking findings with the wider medical community as the team prepares for publication. 


About Aiosyn

Aiosyn is a Dutch medical software company that develops AI-powered pathology solutions for cancer and kidney diseases. Aiosyn’s solutions are integrated into standard pathology workflows. The Aiosyn team has been built upon 20+ years of research experience in the field of pathology and is rooted in the pathology practice.